RNA drugs target genes that were once off-limits

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

A new class of medicines could give doctors the ability to awaken underperforming genes in patients who currently have no treatment options.

Boston-area startup RaNA Therapeutics is developing a novel kind of medicine that can boost the activity of genes that may be silenced or underactive and thus cause disease. The medicine would use a small RNA-like molecule that blocks the function of a long RNA molecule that is hampering the expression of such a gene.

Read the full, original story here: RNA Drugs Target Genes That Were Once Off-Limits

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend